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Self-renewal pathways crucial for maintaining stem cells are deregulated in cancer, raising 
the spectre that cancer therapies targeting such pathways might also ablate normal stem 
cells. As Yilmaz et al. (2006) report in a recent Nature paper, this may not be the case for 
the tumor suppressor protein Pten, which drives the self-renewal of normal hematopoietic 
stem cells and the formation of leukemia cells through different mechanisms.All stem cells—be they pluripotent 
embryonic stem (ES) cells, multipo-
tent tissue-specific stem cells, or 
cancer stem cells—have both the 
capacity to self-renew and to differ-
entiate into many different mature 
cell types. Sustaining homeostatic 
control in normal tissues is achieved 
by the ability of resident stem cells 
to balance these two processes to 
ensure that mature cells are gener-
ated throughout life without deple-
tion of stem cell reserves. Under-
standing how stem cells and their 
microenvironments regulate these 
processes has clinical implications 
because loss of homeostatic con-
trol is a defining characteristic of 
heritable and acquired degenerative 
conditions, aging, and malignant 
transformation.
Cancers of diverse tissues may 
originate from and be maintained by 
minor subpopulations of cells within 
the tumor called cancer stem cells 
(CSCs) (Bonnet and Dick, 1997; Al-
Hajj et al., 2003; Singh et al., 2004). 
It was Dick’s group who identified 
in patients with acute myelogenous 
leukemia (AML) a small subset of 
CSCs (termed leukemia-initiating 
cells) that caused disease when 
transplanted into mice with severe 
combined immunodeficiency (Bon-
net and Dick, 1997). These leuke-
mia-initiating cells shared many 
markers with normal hematopoietic 
stem cells (HSCs) and exhibited extensive proliferative and self-
renewal potential.
Given that CSCs share many 
functional properties with normal 
stem cells, including the poten-
tial for unlimited self-renewal, and 
that many of the critical pathways 
involved in maintaining normal stem 
cell function are also deregulated in 
cancer, therapies directed against 
CSCs targeting such shared path-
ways might also inadvertently deci-
mate normal resident stem cells. 
A study by Yilmaz et al. (2006) in 
Nature now identifies different self-
renewal mechanisms for maintain-
ing pools of leukemic stem cells 
and normal HSCs. The authors 
show that deletion of the Pten 
tumor suppressor gene results in 
generation of leukemic stem cells 
but depletion of normal HSCs. This 
mechanistic distinction may enable 
the design of therapies to combat 
leukemia that target the PTEN path-
way with the goal of killing leukemic 
stem cells without damaging the 
normal stem cell pool.
In our view, the genetic and epi-
genetic events leading to progres-
sion of hematopoietic cells to leuke-
mia must occur in self-renewing 
cells, or else must impart non-self-
renewing cells with self-renewal 
capability, with each event marking 
a more malignant subset, yet leav-
ing behind the less malignant clone 
(Reya et al., 2001; Weissman, 2005). Cell 125Normally, the genetically regulated 
pathways that enable the transition 
from self-renewing stem cells to 
non self-renewing progenitor cells 
ensure that self-renewal is shut off 
as differentiation proceeds. Failure 
to shut off the self-renewal path-
ways could confer self-renewal on 
cells and microenvironments capa-
ble of evading homeostatic regula-
tion. The extent to which CSCs are 
derived directly from transformed 
stem cells, or are the result of 
transformative events that impart 
stem cell-like properties onto more 
committed progenitors, is only just 
beginning to be elucidated and 
is likely to vary depending on the 
type of cancer. However, significant 
deregulation of the mechanisms 
governing normal self-renewal is 
implied because this process is 
usually tightly regulated.
Normal tissue stem cells and 
CSCs share many phenotypic and 
functional properties in addition to 
self-renewal capacity. For example, 
stem cells express high levels of 
many ABC/MDR transporter genes 
(Rossi et al., 2005; Zhou et al., 
2001), which mediate drug efflux. 
Indeed, the ability of AML cells to 
pump out chemotherapeutic agents 
enables them to evade the destruc-
tive effects of these drugs and 
contributes to relapse in leukemia 
patients (Wulf et al., 2001). In fact, 
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patients continues to be the intrin-
sic or acquired resistance of tumor 
cells to chemotherapeutics. Another 
property of HSCs likely to be shared 
by their leukemic progeny is the 
constant movement of these cells 
out of bone marrow into blood to 
seed distant marrow and extramed-
ullary hematopoietic sites (Wright 
et al., 2001). Such a capability may 
explain why myelogenous leuke-
mias are never local but are found 
throughout the bone marrow.
These observations have led to 
studies of the pathways by which 
normal and neoplastic stem cells 
self-renew and differentiate. Many 
pathways known to promote tum-
origenesis—such as the Wnt, Notch, 
and sonic hedgehog signaling path-
ways—have been implicated in stem 
cell self-renewal (Reya et al., 2001). 
Similarly, proteins such as p16 and 
p19 that suppress tumorigenesis also 
inhibit stem cell self-renewal (Molof-
sky et al., 2005). The overexpression 
or absence of genes, such as bmi1, 
that regulate these proteins has been 
implicated in leukemogenesis (Les-
sard and Sauvageau, 2003). The fact 
that so many pathways critical to tum-
origenesis are so intimately linked to 
normal stem cell self-renewal raises 
the spectre that cancer therapies tar-
geting such pathways might ablate 
resident stem cells.
Enter Yilmaz and colleagues 
(2006) with their study of the Pten 
tumor suppressor protein and its 
role in normal HSCs and in leukemic 
transformation. They inactivated 
Pten in the murine hematopoietic 
system using a flox-Cre system (a 
flox Pten allele in Mx-1-Cre mice). 
Loss of Pten in these Ptenfl/flMx-1-
Cre mice quickly led to a myelopro-
liferative disease that progressed 
rapidly to frank leukemia, including 
AML and ALL. Several hematopoi-
etic populations from the Ptenfl/flMx-
1-Cre mice caused leukemia when 
transplanted into irradiated recipi-
ents, but it was the HSC population 
that was most enriched for leuke-
mia-initiating cells.
The investigators report that 
deletion of the Pten gene resulted 
in HSCs being driven rapidly into 230 Cell 125, April 21, 2006 ©2006 Elsevthe cell cycle. This led to transient 
increases in HSC numbers but with 
time resulted in depletion of HSC 
reserves in the mouse bone mar-
row. Pten-deficient HSCs, when 
transplanted into irradiated mice, 
were only capable of short-term 
multilineage reconstitution of the 
hematopoietic system and could not 
stably engraft irradiated recipients 
long-term. Indeed, the Pten-defi-
cient HSCs could not maintain their 
numbers even in wild-type recipi-
ent mice, demonstrating that the 
deficit was intrinsic to these cells. 
The authors found no evidence for 
increased apoptosis underlying the 
depletion of Pten-deficient HSC 
reserves. Taken together, these 
experiments argue that Pten nor-
mally maintains HSCs in a quiescent 
state; in the absence of Pten, HSCs 
are driven into the cell cycle, even-
tually leading to depletion of HSC 
reserves. One possible explanation 
for these events is the unexpected 
quantitative failure of HSCs during 
the active phases of the cell cycle to 
home to bone marrow when placed 
in the bloodstream (although hom-
ing to extramedullary hematopoietic 
sites was not affected) (Fleming et 
al., 1993). Loss of Pten may force 
HSCs out of quiescence resulting 
in depletion of the bone marrow 
HSC pool and the accumulation 
of HSCs in extramedullary hemat-
opoietic sites that cannot sustain 
HSC self-renewal. Crucially, the 
impact of Pten loss on HSC self-
renewal is independent of the role 
that Pten inactivation plays in driv-
ing leukemogenesis. Thus, two dis-
tinct Pten-based mechanisms drive 
HSC self-renewal and the genesis of 
leukemia-initiating cells.
The lipid kinase phosphoinositide 
3-kinase (PI3K) is activated in 
response to a variety of extracel-
lular signals, generating 3′ phos-
phoinositide lipids. These lipids are 
intracellular secondary messengers 
and elicit diverse cellular responses 
(including proliferation, survival, and 
cell growth) by acting upon down-
stream targets such as Akt kinase 
and the mTOR signaling pathway. 
The PTEN tumor suppressor pro-ier Inc.tein is believed to be the central lipid 
phosphatase attenuating PI3K sig-
naling, and loss of PTEN promotes 
the formation of a variety of tumors. 
Deregulation of the mTOR signaling 
pathway is a prominent consequence 
of PTEN inactivation. This pathway 
may be an attractive therapeutic tar-
get for treating tumors carrying inac-
tivated PTEN because mTOR activity 
can be suppressed by a number of 
compounds including rapamycin.
To attempt to therapeutically 
exploit the mechanistic distinction 
between Pten’s activity in stem cell 
self-renewal and leukemogenesis, 
Yilmaz et al. administered rapamy-
cin to the Ptenfl/flMx-1-Cre mice. In 
contrast to control animals, which 
all quickly developed leukemia, the 
Pten-deficient mice treated with 
rapamycin did not. This finding dem-
onstrates that rapamycin can block 
the generation or maintenance of 
leukemia-initiating cells. Importantly, 
rapamycin treatment was effective in 
reducing the frequency of leukemia-
initiating cells even when treatment 
was initiated after the onset of frank 
leukemia.
The impact of rapamycin treat-
ment on the HSC compartment of 
Ptenfl/flMx-1-Cre mice was equally 
impressive. The capacity of HSCs 
from rapamycin-treated Ptenfl/flMx-
1-Cre mice to reconstitute the 
hematopoietic system of irradiated 
recipient mice was restored, and 
their cell-cycle distribution was nor-
malized. Rapamycin treatment also 
eliminated the transient expansion 
of HSCs in Ptenfl/flMx-1-Cre mice 
and prevented depletion of the mar-
row HSC pool, demonstrating that 
the normal self-renewal capacity of 
HSCs had been restored.
The Yilmaz et al. study provides 
key insights into the mechanistic 
heart of both normal stem cells and 
CSCs. The cancer stem cell model of 
tumorigenesis predicts that for can-
cer therapies to be clinically effec-
tive over the long-term, they must 
target the small subset of CSCs 
that is responsible for maintaining 
and spreading the tumor. Drugs that 
target self-renewal potential would 
seem to be attractive candidate can-
cer therapies except for the fact that 
such strategies also might uninten-
tionally eliminate normal bystander 
stem cells that use self-renewal as 
part of their regular functional rep-
ertoire. The elegant work of Yilmaz 
and coworkers, however, demon-
strates that it is possible to identify 
and therapeutically target pathways 
that differentially impact the self-
renewal of normal and CSCs within 
the same tissue. As suggested by 
this study, genes that promote stem 
cell quiescence might be particularly 
amenable to such targeted strate-
gies because although normal stem 
cells thrive in a quiescent world, forc-
ing CSCs to adopt quiescence could 
spell their defeat.RefeRenCeS
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